Antiinfective biotechs face partnering gap

Article Abstract:

Biotech companies entering the antiinfective sector face an added difficulty in finding development and marketing partners due to a shift in the pharmaceutical groups' focus on antiinfectives. However, Vicuron, formed with the merger of US firm Versicor and Italian pharma spin-out Bio-Search Italia, has demonstrated that anti-infection companies could build a decent-market capitalization by combining robust late stage assets with an ability to implement their business plan.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

Diversa restructures, raining question over bioprospecting

Article Abstract:

Diversa of San Diego, California, is planning to restructure in 2006, thereby raising questions about scientific research in the fields of bioprospecting and industrial biotech. The main aim for restructuring is both to conserve its cash pile and to concentrate on building up products sales more rapidly than it has managed earlier.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

A taste of the future

Article Abstract:

Senomyx has signed a clutch of licensing deals with large corporations to commercialize molecules generated through the discovery programme. Senomyx applies the high-throughput screening methods developed for drug discovery, to hunt for novel molecules that modulate the activity of taste receptors.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code: